Clinical trials: Essential Hypertension.
Hypertension
Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)
The purpose of this study is to evaluate long-term safety and tolerability of once daily administration of the combination of Valsartan and Amlodipine 80/5 mg for 52 weeks in patients with essential hypertension.
- Trial name
- NCT00446524
- Testing
- Valsartan + Amlodipine besilate
- Where
- Japan
- Volunteers
- 403 people
- Sponsor
- Novartis
Hypertension
An Extension Trial of GW 906 in Participants With Essential Hypertension
This clinical study was designed to assess the safety and efficacy of long-term dosing of GW906
- Trial name
- NCT07879755
- Testing
- GW906
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Essential Hypertension
Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension
Aim of this study is to compare the blood pressure lowering effect of a new drug formulation of eprosartan. Eprosartan belongs to a class of blood pressure lowering agents used worldwide since years with proven efficacy.
- Trial name
- NCT01631227
- Testing
- Eprosartan, Eprosartan Mesylate
- Where
- 38 sites in Germany, Russia and 1 more
- Volunteers
- 665 people
- Sponsor
- Abbott
Essential Hypertension
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy.
- Trial name
- NCT05526703
- Where
- South Korea
- Volunteers
- 108 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Primary Hypercholesterolemia, Hypertension
To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia
This study is a multicenter, Randomized, double-blind, acitve-controlled, Phase 3 Clinical Trial in 8 weeks for screening, twice Investigational product administer, Follow up visit.
- Trial name
- NCT04659070
- Testing
- Experimental : Ezetimibe / Rosuvastatin + Telmisartan, Active comparator1 : Ezetimibe / Rosuvastatin, Active comparator2 : Telmisartan
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Hypertension
Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension
This is a randomized, comparative Phase 3 trial to investigate the efficacy of fixed dose combination (FDC) of bisoprolol and amlodipine in hypertensive subjects (superiority of FDC over monotherapies).
- Trial name
- NCT01977794
- Testing
- Bisoprolol/Amlodipine (Bisoprolol failed group), Bisoprolol/Amlodipine (Amlodipine failed group)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Hypertension
Comparative Study of Valsartan and Amlodipine Versus Amlodipine Alone in Hypertension
The objective of this study is to evaluate efficacy, safety and tolerability of the valsartan+amlodipine association in patients with mild to moderate essential hypertension, in comparison to amlodipine alone.
- Trial name
- NCT00333489
- Testing
- valsartan
- Where
- Switzerland
- Volunteers
- 551 people
- Sponsor
- Novartis
Hypertension, Vascular Diseases
A Study of the ReCor Medical Paradise System in Clinical Hypertension
RADIANCE-HTN is a randomized, double-blind, sham controlled, 2-cohort study (TRIO and SOLO) designed to demonstrate efficacy and document the safety of the Paradise Renal Denervation System in two distinct populations of…
- Trial name
- RADIANCE-HTN (NCT02649426)
- Testing
- The Paradise® Renal Denervation Ultrasound System
- Where
- 49 sites in United States, Belgium and 5 more
- Volunteers
- 282 people
- Sponsor
- ReCor Medical, Inc.
Hypertension
A Real-world Study of the Safety of Hypertension Medication Therapy in Japanese Patients With Naïve Hypertension
This was a non-interventional, secondary use of data, retrospective, cohort study. The data extracted in this study was used as secondary use of collected patient information in the database, Japan Medical Data Survey (JAMDAS)…
- Trial name
- NCT06683768
- Where
- United States
- Volunteers
- 40,563 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension
The purpose of this study is to evaluate the safety and efficacy of fixed combination of lercanidipine (10 mg or 20 mg) and valsartan (80 mg or 160 mg), lercanidipine and valsartan alone in reducing blood pressure.
- Trial name
- NCT01122251
- Testing
- Lercanidipine + Valsartan, Lercanidipine or Valsartan
- Where
- 2 sites in South Korea
- Volunteers
- 441 people
- Sponsor
- LG Life Sciences
Essential Hypertension
RAS Peptide Profiles in Patients With Arterial Hypertension
Randomized, open-label, parallel-group study conducted at a single center in Switzerland. Patients diagnosed with primary arterial hypertension requiring antihypertensive drug Treatment as well as patients after a 4 week wash out…
- Trial name
- NCT02449811
- Testing
- Perindopril, Olmesartan, Amlodipine
- Where
- Switzerland
- Volunteers
- 107 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Hypertension
Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)
The purpose of this study is to evaluate antihypertensive (lowering blood pressure) effectiveness of three combinations of approved study drugs compared to both study drugs being given alone.
- Trial name
- NCT00092209
- Testing
- MK0954A, hydrochlorothiazide (+) losartan potassium
- Volunteers
- 840 people
- Sponsor
- Organon and Co
Lower Urinary Tract Symptoms, Hypertension
Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension
The aim of this study was to investigate the efficacy and safety of low dose amlodipine alone, or combined with low dose terazosin in male patients with both lower urinary tract symptoms and hypertension.
- Trial name
- NCT00693199
- Testing
- amlodipine, terazosin, amlodipine plus terazosin
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Anhui Medical University
Essential Hypertension
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension
The purpose of this study is to access the efficacy and safety of LCZ696 compared to olmesartan in elderly Asian patients for the treatment of hypertension.
- Trial name
- NCT01615198
- Testing
- Olmesartan, LCZ696
- Where
- 79 sites in China, Hong Kong and 5 more
- Volunteers
- 588 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with chlorthalidone in treating individuals with essential hypertension, compared to treatment with…
- Trial name
- NCT00591773
- Testing
- Azilsartan medoxomil and chlorthalidone, Chlorthalidone
- Where
- 46 sites in United States
- Volunteers
- 551 people
- Sponsor
- Takeda
Evaluation of Cerebral Small Vessel Disease in Patient With Primary Aldosteronism
Evaluation of Cerebral Small Vessel Disease in Patient With Primary Aldosteronism
Hypertension is known to be the major risk factor for stroke. The most common cause of secondary hypertension, primary aldosteronism (PA), is characterized by the excessive secretion of aldosterone and is related to hypertension…
- Trial name
- NCT03821571
- Testing
- Brain MRI
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Essential Hypertension
A Study to Evaluate the Pharmacokinetic, Pharmacodynamic Characteristics and the Safety After Administration by Doses of BR1400-1, BR1400-2, BR1400-3 in Healthy Adult Volunteers
The purpose of this clinical study is to evaluate the pharmacokinetic, pharmacodynamic characteristics and the safety after administration by doses of "BR1400-1", "BR1400-2", "BR1400-3" in healthy volunteers
- Trial name
- NCT06889064
- Testing
- BR1400-1, BR1400-2, BR1400-3
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension
This study will evaluate the safety and efficacy of the fixed combination of valsartan/amlodipine in adult patients with mild to moderate hypertension
- Trial name
- NCT00413049
- Testing
- Valsartan/amlodipine 80/5 mg, Amlodipine 5 mg
- Where
- 12 sites in China
- Volunteers
- 698 people
- Sponsor
- Novartis
Essential Hypertension
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy
The purpose of this study is to evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy in Essential Hypertension Patients
- Trial name
- NCT06121518
- Testing
- D064 and D702, QD
- Where
- South Korea
- Volunteers
- 235 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Hypertension
A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy
Compare the safety and efficacy of amlodipine besylate and candesartan cilexetil combination therapy on patients of essential hypertension who are not properly controlled by candesartan cilexetil monotherapy.
- Trial name
- NCT02368652
- Testing
- Candesartan cilexetil 16mg, Amlodipine 10mg, Candesartan cilexetil 16mg
- Where
- 19 sites in South Korea
- Volunteers
- 181 people
- Sponsor
- HK inno.N Corporation